Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D
Clinical trial NCT03920007 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03920007
- Sponsor
- Atsena Therapeutics Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-10-22
- Primary completion
- 2023-05-19
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.